Sionna Therapeutics (SION) Cash & Equivalents (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Cash & Equivalents data on file, last reported at $63.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 23.42% year-over-year to $63.3 million; the trailing twelve-month figure through Mar 2026 stood at $63.3 million (down 23.42% YoY), and the FY2025 full-year result was $58.5 million, up 54.68% from the prior year.
• Cash & Equivalents grew to $63.3 million in Q1 2026, from $58.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $82.8 million in Q1 2024 to a low of $35.7 million in Q3 2024.
• A 3-year average of $55.2 million and a median of $50.8 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 54.68% in 2025 and dropped 23.42% in 2026, its largest moves.
• Tracing SION's Cash & Equivalents over 3 years: stood at $37.8 million in 2024, then surged by 54.68% to $58.5 million in 2025, then advanced by 8.34% to $63.3 million in 2026.
• Business Quant data shows SION's Cash & Equivalents at $63.3 million in Q1 2026, $58.5 million in Q4 2025, and $50.8 million in Q3 2025.